Skip to main content

Johnson & Johnson’s JNJ-N experimental drug helped reduce symptoms of depression as well as insomnia in patients with major depressive disorder (MDD) in a late-stage trial, the company said in a statement on Wednesday.

The trial was testing the drug, called seltorexant, in patients with both depression and insomnia. Sleep disturbances often accompany depression, despite treatment with commonly-used antidepressant drugs.

In the study, seltorexant met both main and secondary trial goals, showing improvement in depressive symptoms when tested on a scale used to measure the severity of depressive episodes, and also improved sleep disturbance outcomes in patients.

J&J did not disclose the number of patients in the study, but said that the data would be presented at an upcoming meeting.

Seltorexant is one of the 15 assets the New Jersey-based drugmaker bets on for future growth, ahead of looming competition from biosimilars for its blockbuster psoriasis treatment Stelara that are set to enter the market in 2025.

“While we are still waiting for the detailed data for the drug, these initial findings are encouraging and are supportive of J&J’s peak annual sales guidance of $1-$5-billion for the drug”, Morningstar analyst Damien Conover said in an emailed response.

About 21 million U.S. adults in 2021 had at least one episode of MDD, one of the most common chronic mental disorders characterized by a persistent feeling of sadness, according to the National Institutes of Health.

Globally, roughly 280 million people are affected by the disorder, with about 60 per cent experiencing insomnia symptoms, the company estimated.

Seltorexant works by selectively targeting proteins known as orexin-2 receptors, which play a key role in the body’s sleep-wake rhythm.

When the receptors are stimulated for too long, they can lead to excessive release of the stress hormone cortisol, which may contribute to depression and insomnia.

Follow related authors and topics

Authors and topics you follow will be added to your personal news feed in Following.

Interact with The Globe